Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers

Annals of Oncology

Volumn 18, Issue 3, 2007, Pages 485-490

  Alam, S M ^a   Fujimoto, J ^a   Jahan, I ^a   Sato, E ^a   Tamaya, T ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EphB4; EphrinB2; Prognostic indicator; Tumor advancement; Uterine endometrial cancers

Indexed keywords

EPHRIN; EPHRIN B2; EPHRIN B4; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION FUNCTION; ENDOMETRIUM ABLATION; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TISSUE DISTRIBUTION;

EID: 33847640650     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl414     Document Type: Article

References (40)

1. Ephrin Nomenclature Committee. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee [letter]. Cell 1997; 90: 403-404.
2. Gale NW, Holland SJ, Valenzuela DM et al. Eph receptors and ligand comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 1996; 17: 9-19.
3. Pasquale EB. The Eph family of receptors. Curr Opin Cell Biol 1997; 9: 608-619.
4. Gerrety SS, Wang HU, Cheng ZF et al. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999; 4: 403-413.
5. Tickle C, Altabef M. Epithelial cell movements and interactions in limb, neural crest and vasculature. Curr Opin Genet Dev 1999; 9: 455-460.
6. Holder N, Klein R. Eph receptors and ephrins: Effectors of morphogenesis. Development 1999; 126: 2033-2044.
7. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signaling. Nat Rev Mol Cell Biol 2002; 3: 475-486.
8. Bergemann AD, Zhang L, Chiang M-K et al. Ephrin-B3, a ligand for the receptor EphB3, expressed at the midline of the developing neural tube. Oncogene 1998; 16: 471-480.
9. Brambilla R, Bruckner K, Orioli D et al. Similarities and differences in the way transmembrane-types ligands interact with the Elk subclass of Eph receptors. Mol Cell Neurosci 1996; 8: 199-209.
10. Brambilla R, Schnapp A, Casagranda F et al. Membrane bound LERK2 ligand can signal through three different Eph-related receptor tyrosine kinases. EMBO J 1995; 14: 3116-3126.
11. Sakano S, Serizawa R, Inada T et al. Characterization of a ligand for receptor protein-tyrosine kinase HTK expressed in immature haematopoietic cells. Oncogene 1996; 13: 813-822.
12. Bennett BD, Wang Z, Kuang WJ et al. Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily. J Biol Chem 1994; 269: 14211-14218.
13. Easty DJ, Hill SP, Hsu MY et al. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999; 84: 494-501.
14. Vogt T, Stolz W, Weish J et al. Overexpression of Lerk-5/Eplg5 messenger RNA: A novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res 1998; 4: 791-797.
15. Kyokawa E, Takai S, Tanaka M et al. Overexpression of ERK an EPH family receptor protein tyrosine kinase, in various human tumors. Cancer Res 1994; 54: 3645-3650.
16. Tang XX, Jhao H, Robinson ME et al. Implication of EPHB6, EFNB2 and EFNB3 expression in human neuroblastoma. Proc Natl Acad Sci U S A 2000; 97: 10936-10941.
17. Walker-Daniels J, Coffman K, Azimi M et al. Overexpression of EphA2 tyrosine kinase in prostate cancer. Prostate 1999; 41: 275-280.
18. Miyazaki T, Kato H, Fukuchi M et al. EphA2 overexpression correlates with poor prognosis in squamous cell carcinoma. Int J Cancer 2003; 103: 657-663.
19. International Federation of Obstetrics and Gynecology (FIGO) News. FIGO News. Int J Gynaecol Obstet 1989; 28: 189-193.
20. McCarty KS Jr, Miller LS, Cox EB et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716-721.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
22. Davis S, Gale NW, Aldrich TH et al. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 1994; 266: 816-819.
23. Orioli D, Klein R. The Eph receptor family: Axonal guidance by contact repulsion. Trends Genet 1997; 13: 354-359.
24. Brückner K, Pasquale EB, Klein R. Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science 1997; 275: 1640-1643.
25. Katoh MS, Pasquale EB. Multiple in vivo tyrosine phosphorylation sites in EphB receptors. Biochemistry 1999; 38: 14396-14401.
26. Dodelet VC, Pasquale EB. Eph receptors and ephrin ligands: Embryogenesis to tumorigenesis. Oncogene 2000; 19: 5614-5619.
27. Lamorte L, Park M. The receptor tyrosine kinases: Role in cancer progression. Surg Oncol Clin N Am 2001; 10: 271-288.
28. Lawrenson ID, Wimmer-Kleikamp SH, Lock P et al. Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3 expressing 293T and melanoma cells by CrkII and Rho-mediated signaling. J Cell Sci 2002; 115: 1059-1072.
29. Brantly DM, Cheng N, Thompson EJ et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002; 21: 7011-7026.
30. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer 2002; 38 (Suppl 5): S3-S10.
31. Cheng N, Brantly DM, Liu H et al. Blockade of Eph A receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 2002; 1: 2-11.
32. Tang XX, Evans AE, Zhao H et al. High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clin Cancer Res 1999; 5: 1491-1496.
33. Hirai H, Maru Y, Hagiwara K et al. A novel putative tyrosine kinase receptor encoded by the eph gene. Science 1987; 238: 1717-1720.
34. Maru Y, Hirai H, Takaku F. Overexpression confers an oncogenic potential upon the eph gene. Oncogene 1990; 5: 445-447.
35. Robinson D, He F, Pretlow T et al. A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci U S A 1996; 93: 5958-5962.
36. Berclaz G, Andres AC, Albrecht D et al. Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium. Biochem Biophys Res Commun 1996; 226: 869-875.
37. Nikolova Z, Djonov V, Zuercher G et al. Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis. J Cell Sci 1998; 111: 2741-2751.
38. Wenbiao L, Syed AA, Young DJ et al. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 2002; 94: 934-939.
39. Tang XX, Brodeur GM, Campling BG et al. Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma. Clin Cancer Res 1999; 5: 455-460.
40. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996; 56: 370-376.